We investigated whether CA treatment would alter the expression of MMP9 (a class of enzymes that involved in the degradation of the ECM), as well as TGF-β1 and its receptor, TGF-β R1, in BDL-induced liver fibrosis. Here, MMP9 is linked to Hepatic fibrosis.